Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie launches phase III trial of atrasentan

AbbVie launches phase III trial of atrasentan

23rd May 2013

AbbVie has announced the launch of a phase III trial of the investigational compound atrasentan to assess its impact on renal outcomes in patients with diabetic nephropathy.

The aim of the new Sonar study will be to determine the effects of the drug, when added to standard of care, on the progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

AbbVie is commencing this phase III trial after data from phase IIb studies presented at the recent European Renal Association-European Dialysis and Transplant Association congress underlined the treatment's potential efficacy and safety.

Dr James Stolzenbach, divisional vice-president for AbbVie's dyslipidemia and renal division, said: "If validated in phase III, atrasentan has the potential to provide a novel treatment option for type 2 diabetic kidney disease patients worldwide."

Earlier this week, the company announced that it will be allying with Galapagos to assess the potential efficacy of the compound GLPG0634 in the treatment of Crohn's disease.ADNFCR-8000103-ID-801589449-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.